These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 11020029

  • 1. Use of a propafenone metabolic ratio as a measure of CYP2D6 activity.
    Anzenbacherová E, Anzenbacher P, Perlik F, Kvetina J.
    Int J Clin Pharmacol Ther; 2000 Sep; 38(9):426-9. PubMed ID: 11020029
    [Abstract] [Full Text] [Related]

  • 2. CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects.
    Cai WM, Chen B, Cai MH, Zhang YD.
    Zhongguo Yao Li Xue Bao; 1999 Aug; 20(8):720-4. PubMed ID: 10678105
    [Abstract] [Full Text] [Related]

  • 3. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers.
    Cai WM, Chen B, Zhou Y, Zhang YD.
    Clin Pharmacol Ther; 1999 Nov; 66(5):516-21. PubMed ID: 10579479
    [Abstract] [Full Text] [Related]

  • 4. The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects.
    Cai WM, Chen B, Cai MH, Chen Y, Zhang YD.
    Br J Clin Pharmacol; 1999 May; 47(5):553-6. PubMed ID: 10336580
    [Abstract] [Full Text] [Related]

  • 5. Effect of CYP2D6 polymorphisms on the pharmacokinetics of propafenone and its two main metabolites.
    Rouini MR, Afshar M.
    Therapie; 2017 Jun; 72(3):373-382. PubMed ID: 28087064
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L, O'Hara G, Lefebvre M, Lessard E, Gilbert M, Adedoyin A, Champagne J, Hamelin B, Turgeon J.
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [Abstract] [Full Text] [Related]

  • 7. Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects.
    Chen B, Cai WM.
    Acta Pharmacol Sin; 2003 Dec; 24(12):1277-80. PubMed ID: 14653957
    [Abstract] [Full Text] [Related]

  • 8. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M.
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [Abstract] [Full Text] [Related]

  • 9. Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10.
    Doki K, Shirayama Y, Sekiguchi Y, Aonuma K, Kohda Y, Ieda M, Homma M.
    Pharmacogenomics; 2020 Dec; 21(18):1279-1288. PubMed ID: 33203295
    [Abstract] [Full Text] [Related]

  • 10. Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides.
    Botsch S, Heinkele G, Meese CO, Eichelbaum M, Kroemer HK.
    Eur J Clin Pharmacol; 1994 Dec; 46(2):133-5. PubMed ID: 8039531
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects.
    Cai WM, Zhang YD, Chen B, Cai MH, Luo JP, Ling SS.
    Acta Pharmacol Sin; 2001 Oct; 22(10):956-60. PubMed ID: 11749782
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation.
    Chow MS, White CM, Lau CP, Fan C, Tang MO.
    J Clin Pharmacol; 2001 Jan; 41(1):92-6. PubMed ID: 11144999
    [Abstract] [Full Text] [Related]

  • 15. Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.
    Cai WM, Xu J, Chen B, Zhang FM, Huang YZ, Zhang YD.
    Acta Pharmacol Sin; 2002 Nov; 23(11):1040-4. PubMed ID: 12421483
    [Abstract] [Full Text] [Related]

  • 16. Disposition of propafenone in a poor metabolizer of CYP2D6 with Gilbert's syndrome.
    Dilger K, Meisel P, Hofmann U, Eichelbaum M.
    Ther Drug Monit; 2000 Jun; 22(3):366-8. PubMed ID: 10850406
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics.
    Vieira CP, Neves DV, Coelho EB, Lanchote VL.
    Drug Metab Lett; 2018 Jun; 12(1):68-70. PubMed ID: 29676238
    [Abstract] [Full Text] [Related]

  • 19. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M.
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.